According to Merck, on November 14, the company announced that pimiletide hydrochloride capsule (Bejiemei) has been included in China's national medical insurance directory. The approval provides a more affordable treatment option for patients with tenosynovial giant cell tumors (TGCT).

View Source

Disclaimer: This content is for informational purposes only and does not constitute investment advice or encourage the buying or selling of crypto assets. It is intended to provide information about industry developments and is not directly related to the services offered by Gate TR. Although information obtained from third-party sources has been carefully reviewed, Gate TR assumes no responsibility for any errors or omissions. Crypto assets involve high risks and may experience significant price fluctuations. Before making any investment decisions, you should assess your financial situation and risk tolerance, conduct your own research, and make decisions independently.